This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What is in Store for Regeneron (REGN) This Earnings Season?
by Zacks Equity Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Is a Beat in Store for Gilead (GILD) in This Earnings Season?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
by Zacks Equity Research
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.
Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $60.62, moving -0.21% from the previous trading session.
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus
by Zacks Equity Research
Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
by Zacks Equity Research
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Zacks Market Edge Highlights: ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills
by Zacks Equity Research
ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills are part of Zacks Market Edge blog.
Q2 Earnings: Energy and What Else?
by Tracey Ryniec
Expectations are low for this earnings season. Will companies surprise the Street?
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.34, moving -0.03% from the previous trading session.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
by Zacks Equity Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
by Zacks Equity Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead Sciences (GILD) Stock Moves -0.99%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
by Zacks Equity Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.